Source: EURLEX
Language: en
Format: md

Judgment of the General Court (First Chamber) of 18 December 2024 –  
Hecht Pharma v EUIPO – Gufic BioSciences (H 15 Gufic)

(Case T‑520/23)

(EU trade mark – Revocation proceedings – EU figurative mark H 15 Gufic – Genuine use of the mark – Article 58(1)(a) of Regulation (EU) 2017/1001 – Public and outward use – Use in connection with the goods in respect of which the mark was registered)

| 1. | EU trade mark – Surrender, revocation and invalidity – Grounds for revocation – Lack of genuine use of the mark – Proof of use – Genuine use – Concept – Criteria for assessment – Requirement of solid and objective evidence  (European Parliament and Council Regulation 2017/1001, Arts 18(1) and 58(1)(a))  (see paragraphs 22-24, 45-46) |

| 2. | EU trade mark – Lodging of application for EU trade mark – Identification of the goods or services concerned by the trade mark – Use of the general indications in the headings of the classes of the Nice Classification – Scope  (Commission Regulation No 2868/95, Art. 1, Rule 2(4))  (see paragraph 58) |

| 3. | EU trade mark – Surrender, revocation and invalidity – Grounds for revocation – Lack of genuine use of the mark – Use in connection with the goods to which the mark relates – Relevant public’s perception of those goods – Figurative mark H 15 Gufic  (European Parliament and Council Regulation 2017/1001, Arts 18(1)(a) and 58(1)(a))  (see paragraphs 48, 59-63, 65, 70, 73, 68, 74-76, 78) |

Operative part

The Court:

| 1. | Dismisses the action; |

| 2. | Orders Hecht Pharma GmbH to pay the costs. |

[Top](#document1)